Colorectal cancer is often described as a disease whose outlook is determined mainly by how far it has spread, but a new national cohort study suggests that the patient’s age may also shape what happens after apparently curative surgery. Researchers led by O. Almilaji, K. Walker and J. Van Der Meulen examined how age and tumour stage influence the risks of cancer recurrence and death following resection, focusing on patients who underwent surgery intended to remove all detectable disease. Their findings, published in the British Journal of Cancer, add detail to one of oncology’s most consequential questions: why do patients with apparently similar cancers experience very different outcomes?
Curative resection is a central treatment for colorectal cancer. During the operation, surgeons remove the primary tumour along with a section of bowel and nearby lymph nodes, which are examined by pathologists to determine whether malignant cells have spread. When no visible tumour remains, patients may be considered to have undergone curative treatment. Yet microscopic cancer cells can sometimes survive in the body and later produce recurrent disease. Recurrence may appear locally, near the original tumour, or at distant sites such as the liver or lungs. The study investigated how these risks vary across age groups and disease stages after surgery.
Cancer stage is a powerful measure of prognosis because it captures the extent of tumour growth and spread. Early-stage colorectal cancers confined to the bowel wall generally carry a lower risk of recurrence than cancers involving lymph nodes or distant organs. However, stage does not tell the entire story. Tumour biology, treatment received, surgical quality, immune function and other medical conditions can all influence survival. Age may affect several of these factors simultaneously, making it difficult to separate the direct effects of ageing from differences in treatment, disease biology and general health.
The researchers used a national cohort to examine outcomes across a broad population rather than relying on a small group treated at a single hospital. Large observational cohorts can reveal patterns that are difficult to detect in clinical trials, particularly among older adults, who are frequently under-represented in research. By tracking recurrence and mortality after resection, the investigators could distinguish between two related but different outcomes. Recurrence measures whether the cancer returned, while mortality records whether a patient died, potentially from colorectal cancer or from another cause.
That distinction is especially important in older patients. As people age, the probability of dying from cardiovascular disease, respiratory illness, frailty or other cancers increases. In statistical terms, these events act as competing risks: a patient who dies from another cause can no longer experience a colorectal cancer recurrence or die from that cancer. A careful analysis therefore needs to account for both cancer-related hazards and the broader health profile of the population. The study’s focus on age and stage provides a framework for understanding how these competing risks may alter the apparent benefit of surgery and subsequent monitoring.
The findings are relevant to the way clinicians counsel patients after an operation. Two individuals with the same tumour stage may not have identical risks once age and overall health are considered. At the same time, age alone should not be treated as a substitute for an individual assessment. Older adults are a highly diverse group: one person in their seventies may be physically active with few medical problems, while another may have severe frailty and multiple conditions. Functional status, nutrition, cognitive health and the ability to tolerate chemotherapy can all be more informative than chronological age by itself.
The results may also influence follow-up strategies. Surveillance after colorectal cancer surgery commonly involves blood tests for tumour markers, imaging and colonoscopy, with the intensity and duration shaped by the risk of recurrence. If recurrence risk differs substantially according to both stage and age, follow-up programmes could eventually become more precisely tailored. Patients at elevated risk might benefit from closer imaging or earlier specialist review, whereas those whose likelihood of recurrence is low but whose risk of other illnesses is high may need a more balanced approach. Such decisions would require evidence beyond a single cohort, including studies of patient preferences and the effects of surveillance on survival.
The study also highlights a persistent challenge in cancer research: older age can be associated with both undertreatment and overtreatment. Some older patients may receive less intensive chemotherapy because of concerns about side effects, even when they could benefit from treatment. Others may undergo aggressive therapy despite limited physiological reserve. Understanding the separate contributions of stage, recurrence risk and competing mortality could help clinicians make decisions based on expected benefit rather than age-based assumptions. The goal is not simply to extend life, but to improve the quality and relevance of the years that treatment may preserve.
Because the research is observational, its results should be interpreted as evidence of patterns and associations rather than proof that age or any specific treatment directly causes an outcome. National data can provide exceptional statistical power, but medical records may not contain every factor that affects prognosis, including detailed measures of frailty, molecular tumour characteristics, treatment adherence and patient preferences. Even so, the analysis offers an important population-level perspective on what happens after curative colorectal cancer surgery. As colorectal cancer becomes increasingly common in older populations, integrating age, stage and individual health into post-operative care could make cancer treatment more precise, more equitable and more closely aligned with the realities of patients’ lives.
Subject of Research: The effect of older age and colorectal cancer stage on recurrence and mortality after curative resection.
Article Title: The effect of older age and stage on risk of recurrence and mortality following curative resection, in a national cohort of patients with colorectal cancer.
Article References: Almilaji, O., Walker, K., Van Der Meulen, J. et al. “The effect of older age and stage on risk of recurrence and mortality following curative resection, in a national cohort of patients with colorectal cancer.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03553-4
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03553-4; publication date: 21 July 2026
Keywords: colorectal cancer, cancer recurrence, mortality, older age, cancer stage, curative resection, surgery, national cohort, cancer surveillance, oncology
